Llorente & Cuenca S.A. (LLYC)
Madrid Exchange · Spain · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 5.250 |
|---|---|
| 52-week range | 4.240 – 8.200 |
| Return, 1 month / 3 months | −22.8% / +7.1% |
| Return, 1 year / 3 years | −35.2% / −40.1% |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 38.2% |
| Worst drawdown (1 year) | -46.3% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Llorente & Cuenca is a communications and public affairs consultancy based in Madrid. It advises companies and institutions on corporate communication, public affairs, crisis management and digital marketing, helping them manage their reputation and relationships with stakeholders. Its clients include large businesses and organisations, and the firm operates across Spain and Latin America through a network of offices and partner arrangements.
On this site Llorente & Cuenca S.A. appears as a stock on the Madrid Exchange (Spain), code LLYC, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Llorente & Cuenca S.A. (LLYC) trades on the Madrid Exchange in Spain. It last closed at EUR 5.250 on 22 October 2026.
Its price-based Market X-Ray is 33 out of 100 (a weak price profile), ranking 187 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 35.2% and over the last three months it rose 7.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.9% | ||
| From 52-week high | -35.2% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.1% | ||
| 6-month return | -5.4% | ||
| 12-month return, skipping the last month | -16.0% | ||
| Stability (higher is calmer) | 15 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.3% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −9.5% |
|---|---|
| 1 month | −22.8% |
| 3 months | +7.1% |
| 6 months | −5.4% |
| 1 year | −35.2% |
| 3 years | −40.1% |
| 5 years | −59.2% |
Signals
| 50-day / 200-day average | 5.549 / 5.639 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.131 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Jul 2025 | EUR 0.1720 |
| 16 Jul 2024 | EUR 0.1720 |
| 13 Jul 2023 | EUR 0.1320 |
| 13 Jul 2022 | EUR 0.1320 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.